Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo

The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.

Medical Daily

FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables

FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here's who it's for.

Medical Daily

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who dislike injectable treatments for heart disease. The drug is priced at $10.50 daily and will be available soon. Merck…

The Economic Times

FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol

The Independent UK

Drugmaker Merck announces approval of new cholesterol-fighting drug

Lipfendra can be taken in conjunction with or an alternative to statins, the most prescribed medication in the US

The Guardian - US

FDA Clears First Of Its Kind Cholesterol Medication: Lipfendra Makes History

The U.S. Food and Drug Administration has approved Merck's Lipfendra (enlicitide), making it the first oral PCSK9 inhibitor available in the United States and offering millions of patients with high cholesterol a new alternative to injectable therapies.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Hair Transplants Carry A Life-Changing Risk That Nobody Is Talking About

For many people, a hair transplant feels like the end of a long battle with hair loss. But the medication often recommended afterward has become the center of an increasingly bitter medical debate. This investigation examines what clinics tell patients, what regulators now warn, and why some experts believe informed…

Bored Panda

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

Barchart

Pet Stocks Have Slipped Since COVID. Is This an Investing Opportunity?

Americans still love their pets, and ownership keeps rising. So what happened to pet stocks?

Kiplinger

New Jersey woman warns that a $1.8 billion AI plant is being built next to Manhattan Bagel. Then asked who’s actually benefiting

250 megawatts and a lot of questions.

We Got This Covered

A New Vaccine Option Is Now Available for Kids with Diabetes, Heart Disease, or Other Chronic Conditions

FDA approved Capvaxive for kids 2-17 with chronic conditions like diabetes and heart disease, June 18, 2026. Here's what families managing pediatric chronic illness need to know.

Medical Daily

The $11 Billion Reason TECH Stock Is Up Today

Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?

Barchart

How to Buy Merck Stock for a 10% Discount or Achieve an 11% Annual Return

On Monday, with Merck trading at $119.60, the August put option with a strike price of $110 was trading around $2.03. Traders selling this put would receive $230 in option premium. In return for receiving this premium, they have an obligation to buy 100 shares of MRK for $110.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

CKGSB Hosts 10th Economic Symposium in Beijing, Spotlighting China-ASEAN and China-Europe Economic Ties

BEIJING, June 22, 2026 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB), a leading business school in China, hosted its 10th Economic Symposium at its new Beijing campus. The forum brought together ambassadors, policymakers, business leaders, and scholars to examine China's economic outlook and its evolving relationships with ASEAN…

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

AAP

The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains

ZURICH, June 9, 2026 /PRNewswire/ -- The Hashgraph Group (THG) today announced a strategic collaboration with science and technology company Merck, that extends its TrackTraceDigital Product Passport (DPP) platform. Built on Hedera and designed to support compliance requirements for the global supply chain industry, the collaboration aims to meet the…

MarketBeat

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months. Levy said the company is

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president of strategy, said during a session hosted by RBC Capital Markets. Peters said Exelixis’ guidance

Kiplinger

Dow Hits New High as Warsh Takes Fed Oath: Stock Market Today

President Donald Trump welcomed Fed Chair Kevin Warsh the same way President Ronald Reagan welcomed Fed Chair Alan Greenspan.

MarketBeat

Merck KGaA Q1 Earnings Call Highlights

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

MarketBeat

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

The Conversation

Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients

Some clinical trials aren’t designed to answer scientific questions. They’re designed to market drugs. In our recently published research, my team and I analyzed over 34,000 industry-funded trials and found that hundreds of studies across seven medical fields were likely designed to promote a drug to physicians rather than to…

Barchart

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Barchart

This Merck (MRK) Stock Bullish Diagonal Trade Targets a Price of $130 by June 18

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.